{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T07:11:30Z","timestamp":1772608290445,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004095","name":"Kyowa Hakko Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.clml.2019.03.004","type":"journal-article","created":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T23:04:45Z","timestamp":1553295885000},"page":"326-331","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Mogamulizumab for the Treatment of Adult T-cell Leukemia\/Lymphoma"],"prefix":"10.1016","volume":"19","author":[{"given":"Hiroshi","family":"Ureshino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuharu","family":"Kamachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2019.03.004_bib1","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1182\/blood-2015-03-632489","article-title":"ATL-Prognostic Index Project. Treatment and survival among 1594 patients with ATL","volume":"126","author":"Katsuya","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.004_bib2","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1200\/JCO.2007.11.9958","article-title":"VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801","volume":"25","author":"Tsukasaki","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.03.004_bib3","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1182\/blood-2009-10-247510","article-title":"Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study","volume":"116","author":"Hishizawa","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.004_bib4","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","article-title":"Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study","volume":"30","author":"Ishida","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.03.004_bib5","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1200\/JCO.2016.67.8250","article-title":"Pretransplantation anti-CCR4 antibody mogamulizumab against adult T-cell leukemia\/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality","volume":"34","author":"Fuji","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.03.004_bib6","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/bjh.13338","article-title":"Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study","volume":"169","author":"Ishida","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2019.03.004_bib7","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2141.1991.tb08051.x","article-title":"Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87)","volume":"79","author":"Shimoyama","year":"1991","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2019.03.004_bib8","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1046\/j.1365-2141.2001.02737.x","article-title":"A\u00a0new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303","volume":"113","author":"Yamada","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2019.03.004_bib9","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1182\/blood.V76.10.2065.2065","article-title":"Expression of P-glycoprotein in adult T-cell leukemia cells","volume":"76","author":"Kuwazuru","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.004_bib10","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1182\/blood.V79.2.477.477","article-title":"Mutations of the p53 gene in adult T-cell leukemia","volume":"79","author":"Sakashita","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.004_bib11","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1056\/NEJM199506293322603","article-title":"Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine","volume":"332","author":"Gill","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.03.004_bib12","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJM199506293322604","article-title":"Treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa","volume":"332","author":"Hermine","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.03.004_bib13","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1056\/NEJM199511093331911","article-title":"Interferon alfa and zidovudine in adult T-cell leukemia-lymphoma. Lymphoma Study Group of the Japan Clinical Oncology Group","volume":"333","author":"Tobinai","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.03.004_bib14","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1200\/JCO.2010.28.0669","article-title":"Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia\/lymphoma showing improved survival in the leukemic subtypes","volume":"28","author":"Bazarbachi","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.03.004_bib15","first-page":"3625","article-title":"Clinical significance of CCR4 expression in adult T-cell leukemia\/lymphoma: its close association with skin involvement and unfavorable outcome","volume":"9","author":"Ishida","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2019.03.004_bib16","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1074\/jbc.M210665200","article-title":"The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity","volume":"278","author":"Shinkawa","year":"2003","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.clml.2019.03.004_bib17","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1158\/0008-5472.CAN-03-2068","article-title":"Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma","volume":"64","author":"Niwa","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2019.03.004_bib18","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-09-2697","article-title":"Defucosylated humanized aanti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia\/lymphoma","volume":"16","author":"Ishii","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2019.03.004_bib19","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1200\/JCO.2009.25.3575","article-title":"Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma","volume":"28","author":"Yamamoto","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.03.004_bib20","article-title":"Mogamulizumab versus investigator choice of chemotherapy regimen in relapsed\/refractory adult T-cell leukemia\/lymphoma","author":"Phillips","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2019.03.004_bib21","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1007\/s12185-017-2270-9","article-title":"Safety and efficacy of mogamulizumab in patients with adult T-cell leukemia\u2013lymphoma in Japan: interim results of postmarketing all-case surveillance","volume":"106","author":"Ishitsuka","year":"2017","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2019.03.004_bib22","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clml.2016.09.009","article-title":"A\u00a0multicenter retrospective study of mogamulizumab efficacy in adult T-cell leukemia\/lymphoma","volume":"17","author":"Iyama","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2019.03.004_bib23","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00277-018-3502-7","article-title":"Clinical impact of the CONUT score and mogamulizumab in adult T cell leukemia\/lymphoma","volume":"98","author":"Ureshino","year":"2019","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2019.03.004_bib24","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/ejh.12863","article-title":"Effects of mogamulizumab in adult T-cell leukemia\/lymphoma in clinical practice","volume":"98","author":"Sekine","year":"2017","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2019.03.004_bib25","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.bbmt.2014.12.020","article-title":"A\u00a0retrospective analysis of treatment outcomes in adult T cell leukemia\/lymphoma patients with aggressive disease treated with or without allogeneic stem cell transplantation: a single-center experience","volume":"21","author":"Kawada","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.clml.2019.03.004_bib26","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s12185-012-1177-8","article-title":"Unrelated cord blood transplantation for patients with adult T-cell leukemia\/lymphoma: experience at a single institute","volume":"96","author":"Nakamura","year":"2012","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2019.03.004_bib27","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1172\/JCI17702","article-title":"Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia","volume":"112","author":"Trenado","year":"2003","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.clml.2019.03.004_bib28","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.bbmt.2016.05.017","article-title":"Mogamulizumab treatment prior to allogeneic hematopoietic stem cell transplantation induces severe acute graft-versus-host disease","volume":"22","author":"Sugio","year":"2016","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.clml.2019.03.004_bib29","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/bjh.15123","article-title":"Follow-up of a randomised phase II study of chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: impact on allogeneic haematopoietic stem cell transplantation","volume":"184","author":"Ishida","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2019.03.004_bib30","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.3324\/haematol.2017.184564","article-title":"Outcomes of patients with relapsed aggressive adult T-cell leukemia-lymphoma: clinical effectiveness of anti-CCR4 antibody and allogeneic hematopoietic stem cell transplantation","volume":"103","author":"Fuji","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2019.03.004_bib31","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1200\/JCO.18.00501","article-title":"Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report","volume":"37","author":"Cook","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.03.004_bib32","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1158\/2326-6066.CIR-15-0303","article-title":"Effector regulatory T cells reflect the equilibrium between antitumor immunity and autoimmunity in adult T-cell leukemia","volume":"4","author":"Ureshino","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.clml.2019.03.004_bib33","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41409-018-0291-5","article-title":"Safety of mogamulizumab for relapsed ATL after allogeneic hematopoietic cell transplantation","volume":"54","author":"Inoue","year":"2019","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.clml.2019.03.004_bib34","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/path.4699","article-title":"CCR4 frameshift mutation identifies a distinct group of adult T cell leukaemia\/lymphoma with poor prognosis","volume":"238","author":"Yoshida","year":"2016","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.clml.2019.03.004_bib35","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1182\/blood-2018-02-835991","article-title":"CCR4 mutations associated with superior outcome of adult T-cell leukemia\/lymphoma under mogamulizumab treatment","volume":"132","author":"Sakamoto","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.004_bib36","doi-asserted-by":"crossref","first-page":"e1405204","DOI":"10.1080\/2162402X.2017.1405204","article-title":"Deep sequencing of the T cell receptor visualizes reconstitution of T cell immunity in mogamulizumab-treated adult T cell leukemia","volume":"7","author":"Shindo","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.clml.2019.03.004_bib37","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/cas.12116","article-title":"Stevens-Johnson Syndrome associated with mogamulizumab treatment of adult T-cell leukemia\/lymphoma","volume":"104","author":"Ishida","year":"2013","journal-title":"Cancer Sci"},{"key":"10.1016\/j.clml.2019.03.004_bib38","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/hon.2242","article-title":"Late onset toxic epidermal necrolysis induced by mogamulizumab, an anti-CC chemokine receptor 4 antibody for the treatment of adult T-cell leukaemia\/lymphoma","volume":"35","author":"Shiratori","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2019.03.004_bib39","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/1346-8138.12419","article-title":"Effect of anti-CCR4 monoclonal antibody (mogamulizumab) on adult T-cell leukemia \u2013 lymphoma: cutaneous adverse reactions may predict the prognosis","volume":"41","author":"Yonekura","year":"2014","journal-title":"J\u00a0Dermatol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019301077?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019301077?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:32:47Z","timestamp":1761870767000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265019301077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S2152265019301077"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2019.03.004","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mogamulizumab for the Treatment of Adult T-cell Leukemia\/Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2019.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}